Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
The closing price of Cytokinetics Inc (NASDAQ: CYTK) was $60.31 for the day, down -2.09% from the previous closing price of $61.6. In other words, the price has decreased by -$2.09 from its previous closing price. On the day, 1.99 million shares were traded. CYTK stock price reached its highest trading level at $62.265 during the session, while it also had its lowest trading level at $59.71.
Ratios:
Our analysis of CYTK’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 6.88 and its Current Ratio is at 6.88.
On April 24, 2025, Barclays started tracking the stock assigning a Overweight rating and target price of $55.
On February 07, 2025, Citigroup started tracking the stock assigning a Buy rating and target price of $86.Citigroup initiated its Buy rating on February 07, 2025, with a $86 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Dec 08 ’25 when Callos Andrew sold 1,042 shares for $65.96 per share. The transaction valued at 68,730 led to the insider holds 50,660 shares of the business.
Callos Andrew sold 52,486 shares of CYTK for $3,461,452 on Dec 05 ’25. The EVP, Chief Commercial Officer now owns 50,660 shares after completing the transaction at $65.95 per share. On Dec 05 ’25, another insider, ANDREW CALLOS, who serves as the Officer of the company, bought 53,528 shares for $66.54 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CYTK now has a Market Capitalization of 7374409216 and an Enterprise Value of 7762127360. For the stock, the TTM Price-to-Sale (P/S) ratio is 84.56. Its current Enterprise Value per Revenue stands at 89.004 whereas that against EBITDA is -13.78.
Stock Price History:
The Beta on a monthly basis for CYTK is 0.56, which has changed by 0.22611463 over the last 52 weeks, in comparison to a change of 0.13042927 over the same period for the S&P500. Over the past 52 weeks, CYTK has reached a high of $69.33, while it has fallen to a 52-week low of $29.31. The 50-Day Moving Average of the stock is -2.89%, while the 200-Day Moving Average is calculated to be 34.67%.
Shares Statistics:
CYTK traded an average of 2.01M shares per day over the past three months and 1647390 shares per day over the past ten days. A total of 122.12M shares are outstanding, with a floating share count of 119.85M. Insiders hold about 1.98% of the company’s shares, while institutions hold 115.57% stake in the company. Shares short for CYTK as of 1764288000 were 12948508 with a Short Ratio of 6.44, compared to 1761868800 on 13786011. Therefore, it implies a Short% of Shares Outstanding of 12948508 and a Short% of Float of 13.719999999999999.
Earnings Estimates
A comprehensive evaluation of Cytokinetics Inc (CYTK) is underway, with the input of 8.0 analysts contributing to its current rating.The consensus estimate for the next quarter is -$1.59, with high estimates of -$1.34 and low estimates of -$1.79.
Analysts are recommending an EPS of between -$4.95 and -$6.81 for the fiscal current year, implying an average EPS of -$5.97. EPS for the following year is -$5.98, with 9.0 analysts recommending between -$4.62 and -$7.21.
Revenue Estimates
For the next quarter, 17 analysts are estimating revenue of $19.5M. There is a high estimate of $48.91M for the next quarter, whereas the lowest estimate is $7M.
A total of 19 analysts have provided revenue estimates for CYTK’s current fiscal year. The highest revenue estimate was $153.83M, while the lowest revenue estimate was $70.28M, resulting in an average revenue estimate of $83.37M. In the same quarter a year ago, actual revenue was $18.47MBased on 17 analysts’ estimates, the company’s revenue will be $139.17M in the next fiscal year. The high estimate is $243M and the low estimate is $54.1M.
